Medical Science Liaisons are among the most highly credentialed professionals in the pharmaceutical industry. Most hold PhDs, PharmDs, or MDs. They are hired for their scientific depth, their ability to hold peer-to-peer conversations with the world's leading clinicians, and their capacity to translate complex clinical data into actionable medical strategy.
And yet, if you shadow an MSL for a week, you will find that a startling proportion of their time is spent not on scientific exchange, but on logistics. Searching PubMed for a physician's recent publications. Cross-referencing ClinicalTrials.gov to see who is running relevant studies. Copying data from one spreadsheet to another to build a KOL profile. Updating a CRM that nobody upstream ever reads. Planning a route through a territory using Google Maps and institutional knowledge.
This is not a failure of individual MSLs. It is a structural problem with how the profession has been supported — or more accurately, how it has not been supported — by technology. The MSL role has evolved dramatically over the past two decades, but the tools available to MSL teams have largely remained fragmented, manual, and borrowed from adjacent functions like sales.
This guide breaks down the complete MSL workflow from end to end: what each stage involves, where the work actually happens, and where the profession is headed as better infrastructure finally arrives.
What Is an MSL?
A Medical Science Liaison is a field-based medical affairs professional who serves as the scientific bridge between a pharmaceutical or biotech company and the external medical community. Unlike sales representatives, MSLs do not promote products. Their role is non-promotional by design and by regulation. They engage in peer-to-peer scientific exchange with healthcare professionals — sharing clinical data, discussing disease-state education, gathering medical insights, and supporting investigator-initiated research.
MSLs typically report into the Medical Affairs organization, not the commercial side of the business. Their conversations with physicians are governed by different compliance frameworks than those that govern sales interactions. An MSL can discuss data from ongoing clinical trials, off-label scientific information, and emerging research in ways that a sales representative cannot. This distinction is not incidental — it is foundational to the value MSLs provide.
The typical MSL holds an advanced scientific degree. Many have published research themselves. They are hired because they can sit across from a department chair at an academic medical center and have a substantive conversation about mechanism of action, trial design, or real-world evidence — not because they can close a deal. In practice, MSLs function as the company's scientific ambassadors, and the credibility of that role depends entirely on their independence from commercial objectives.
Most MSL teams are organized by therapeutic area and geography. A single MSL might cover an entire state or a cluster of major metropolitan areas, managing relationships with dozens — sometimes over a hundred — key opinion leaders, investigators, and institutional decision-makers. The breadth of this coverage, combined with the depth of scientific preparation required for each interaction, is what makes the MSL workflow so demanding.
The End-to-End MSL Workflow
The MSL workflow is often described in simple terms — find the right doctors, meet with them, report what you learn. In reality, each of those steps contains layers of complexity that are invisible to anyone who has not done the work. What follows is a detailed breakdown of each stage, drawn from the actual day-to-day experience of field-based MSLs.
KOL Identification & Prioritization
Every MSL engagement begins with a question: who should we be talking to? The answer is less obvious than it appears. The physicians who matter most for a given therapeutic area or product are not always the ones with the highest publication counts or the most prominent conference presentations. Depending on the company's strategic objectives, the priority list might include clinical trialists, formulary decision-makers, community-based treaters with high patient volumes, emerging researchers, or guideline authors.
Traditionally, MSL teams identify and prioritize KOLs through a combination of methods: manual PubMed searches to find prolific authors in a disease area, reviews of conference proceedings and speaker lists, peer referrals from colleagues and internal medical directors, and purchased KOL lists from vendor databases. Each of these methods captures a different slice of the landscape, and none of them is complete on its own.
The hardest gap to fill is at the community level. Academic KOLs are relatively easy to find — they publish, they present, they serve on advisory boards. But in many therapeutic areas, the physicians who treat the most patients are community-based clinicians who may not have a single publication to their name. They influence prescribing through local peer networks, hospital P&T committees, and regional medical societies. Identifying these individuals requires data sources that most MSL teams simply do not have access to, or do not have the time to aggregate.
Prioritization adds another layer. Once you have a list of potential KOLs, you need a framework for deciding who gets your limited time. Most teams use a tiering system — Tier 1 KOLs receive the most frequent engagement, Tier 3 KOLs receive the least — but the criteria for tiering vary widely. Some organizations tier purely on publication volume. Others incorporate clinical trial involvement, speaking activity, payment data, institutional affiliation, and geographic relevance. The best teams build multidimensional profiles that weight these signals according to their strategic context.
In practice, most MSL teams still manage this process in spreadsheets. A new MSL joining a territory will often inherit a predecessor's Excel file — partially updated, inconsistently formatted, and missing the rationale behind each tier assignment. This is where the workflow begins, and it is already fragile.
KOL Profiling & Research
Once a KOL has been identified as a priority, the MSL needs to build a comprehensive profile before any outreach occurs. This is the research phase, and it is among the most time-consuming steps in the entire workflow.
A thorough KOL profile typically includes the physician's publication history in the relevant therapeutic area, their involvement in clinical trials (as principal investigator, sub-investigator, or steering committee member), any NIH or foundation grant funding they have received, their history of payments from pharmaceutical companies (available through Open Payments), their conference speaking engagements and poster presentations, their institutional affiliations and leadership roles, and their participation in guideline committees or professional societies.
Building this profile requires pulling data from multiple disconnected sources. PubMed for publications. ClinicalTrials.gov for trial involvement. The NIH Reporter database for grants. The CMS Open Payments database for industry payments. Conference websites for speaking history. Institutional websites for affiliations. LinkedIn, occasionally, for career trajectory.
An experienced MSL can spend 30 to 60 minutes building a single KOL dossier. For a territory with 80 to 120 KOLs, the math is sobering. And these profiles are not static — publications appear monthly, trials start and end, affiliations change. Keeping profiles current is a maintenance burden that compounds over time. Many teams acknowledge that their KOL data is out of date within weeks of creation.
The quality of this research directly determines the quality of the engagement that follows. An MSL who walks into a meeting without knowing that a physician just published a critical paper on a relevant endpoint, or just enrolled their first patient in a competitive trial, has already undermined the peer-to-peer dynamic that makes the MSL role valuable. Profiling is not paperwork — it is the foundation of credibility.
Territory Planning
MSLs are field-based professionals, which means their effectiveness is shaped by geography. Territory planning is the process of mapping KOLs to locations, allocating time across a coverage area, and building a cadence of engagement that reflects both strategic priority and logistical reality.
A typical MSL territory might span several hundred miles and include academic medical centers, community hospitals, research institutions, and private practices. The MSL needs to balance high-priority KOLs who warrant monthly or bimonthly visits against a broader set of physicians who need quarterly or semi-annual touchpoints. Travel time, institutional access policies, and physician availability all constrain the schedule.
Good territory planning requires a clear view of coverage gaps — physicians who should be receiving regular engagement but are not, often because they are geographically isolated or because the MSL has been pulled toward higher-profile accounts. It also requires alignment with Medical Affairs strategy. If the company is preparing for a label expansion, the territory plan needs to shift toward physicians who are relevant to the new indication. If a competitive product just launched, the plan needs to prioritize KOLs in markets where that competitor is gaining traction.
Most MSLs build their territory plans in PowerPoint or Excel, sometimes supplemented by a CRM's rudimentary mapping features. The plans are reviewed quarterly with their managers but rarely updated in real time as circumstances change. The result is a planning process that is perpetually retrospective rather than adaptive.
Outreach & Engagement Planning
Before an MSL reaches out to a KOL, they need to have a reason for the interaction that is grounded in science, not in a calendar cadence. This is where pre-call planning happens, and it is one of the most nuanced parts of the MSL workflow.
Effective pre-call planning begins with identifying a topic of mutual scientific interest. Has the KOL recently published something that intersects with the company's clinical program? Is there new data from a recent congress that the KOL would find valuable? Has the KOL asked a question in a previous interaction that the MSL can now follow up on with new evidence? The best MSL interactions feel like a continuation of an ongoing scientific dialogue, not a series of disconnected check-ins.
Compliance adds a critical layer to outreach planning. MSL interactions must be non-promotional, which means the MSL cannot initiate a conversation for the purpose of influencing prescribing behavior. The topics discussed must be scientifically balanced. Any materials shared must be approved for use in the medical context. These guardrails are not optional — violations can result in regulatory action, and most pharmaceutical companies have medical-legal-regulatory (MLR) review processes that govern what MSLs can and cannot discuss.
The outreach itself — email, phone call, or in-person visit request — needs to communicate scientific value in a sentence or two. Physicians are busy. An MSL email that reads like a generic meeting request will be ignored. One that references the physician's recent work and offers a specific scientific discussion point is far more likely to get a response. This level of personalization requires the kind of deep profiling described in the previous section, which is why the earlier stages of the workflow have such a direct impact on downstream success.
Scientific Exchange
The scientific exchange is the core of the MSL role — the reason the position exists. Everything else in the workflow is preparation for or follow-up from this moment: a peer-to-peer conversation between a company scientist and an external expert about data, disease, and patient care.
Productive scientific exchanges share certain characteristics. They are bidirectional. The MSL is not delivering a presentation — they are engaging in a dialogue. They bring data and context from the company's clinical program, and they listen to the physician's perspective on unmet needs, treatment patterns, and evidence gaps. The best MSL interactions generate insights that neither party would have arrived at independently.
Scientific exchanges take many forms. One-on-one meetings in a physician's office are the most common, but MSLs also engage KOLs at medical congresses, during advisory boards, through medical education programs, and increasingly through virtual interactions. Congress interactions are particularly valuable because they create a natural context for scientific discussion — new data has just been presented, and KOLs are actively processing and debating its implications.
Advisory boards represent a more structured form of scientific exchange. These are meetings where a company convenes a group of external experts to provide guidance on a specific scientific or clinical question. MSLs often play a central role in identifying and recruiting advisory board participants, and the insights generated from these meetings can directly influence clinical development strategy, medical communications, and evidence generation plans.
What distinguishes a great MSL from an adequate one is the quality of these interactions. A great MSL reads the physician's research before the meeting, anticipates their questions, brings relevant data that the physician may not have seen, and creates an environment where the physician shares their genuine clinical perspective rather than giving polite but uninformative responses. This requires preparation, scientific fluency, and relational skill — none of which can be automated, but all of which can be better supported.
Insights Capture & Reporting
After every meaningful interaction, an MSL is expected to document what they learned. In theory, this insights capture process is one of the most valuable functions an MSL performs. MSLs have direct access to the physicians who treat patients, design trials, and shape clinical practice. The insights they gather — about unmet needs, competitive perceptions, barriers to adoption, clinical experience with a product — should flow directly into strategic decision-making across Medical Affairs, R&D, and commercial planning.
In practice, this rarely happens. The typical insights capture workflow involves an MSL typing a few sentences into a CRM text field, categorizing the insight with a dropdown tag, and moving on to their next meeting. These notes accumulate in a database that is technically accessible but practically invisible. Medical Affairs leadership may review aggregated insight reports quarterly, but the richness and nuance of individual insights is lost in the aggregation. R&D and commercial teams almost never see the raw data.
The problem is not that MSLs fail to capture insights. The problem is that the systems they use are not designed to surface, synthesize, or route insights to the people who need them. A single MSL might capture a critical observation — say, that physicians in a particular geography are switching away from the company's product because of a tolerability concern that does not appear in claims data — but that insight sits in a CRM alongside hundreds of routine interaction notes, with no mechanism for escalation or pattern detection.
The best Medical Affairs organizations have begun to treat insights as a strategic asset rather than a compliance requirement. They are investing in processes that categorize insights by theme, route them to relevant stakeholders, and track whether they influence downstream decisions. But even in these organizations, the technology is usually lagging behind the intent.
Internal Reporting & Impact Measurement
MSL teams are under increasing pressure to demonstrate their value in quantitative terms. This pressure comes from two directions: from Medical Affairs leadership, who need to justify headcount and budget, and from the broader organization, which is accustomed to measuring field force effectiveness through metrics borrowed from the commercial side.
The standard KPIs for MSL teams include interaction volume (number of KOL meetings per month), territory coverage (percentage of tiered KOLs engaged within a given period), insight submission count, and activity metrics like congress attendance and advisory board support. Some organizations also track response time to medical information requests and involvement in investigator-initiated trial support.
The fundamental problem with these metrics is that they measure activity, not impact. An MSL who has 15 interactions per month but generates no meaningful insights and builds no durable relationships will score well on traditional KPIs. An MSL who has 8 deeply substantive interactions that yield strategic insights and strengthen the company's position with three critical thought leaders will appear underperforming by the same measures.
Impact measurement for MSLs remains one of the unsolved problems in Medical Affairs. Some organizations have moved toward qualitative assessments — evaluating the strategic relevance of insights, the depth of KOL relationships, and the MSL's contribution to cross-functional initiatives. Others are experimenting with leading indicators like KOL sentiment shifts over time or the correlation between MSL engagement and investigator-initiated trial submissions. But there is no industry consensus on what "MSL impact" looks like in a dashboard, and the metrics that are easiest to capture are often the least meaningful.
Where the Workflow Breaks Down
If the workflow described above sounds labor-intensive, that is because it is. But the real issue is not the volume of work — it is the fragmentation. Each stage of the MSL workflow typically involves a different tool, a different data source, and a different process, none of which are connected to the others.
KOL identification might happen in a vendor database like Veeva KOL Management or a purchased list from a data provider. Profiling happens across PubMed, ClinicalTrials.gov, Open Payments, and institutional websites. Territory planning might be done in Excel or a standalone mapping tool. Outreach and engagement tracking live in a CRM — usually Veeva CRM or Salesforce, configured for sales workflows and awkwardly adapted for medical use. Insights capture happens in the same CRM but is rarely connected to the profiling data. Reporting is pulled together in PowerPoint decks assembled manually before quarterly business reviews. For a deeper look at these structural problems, consider exploring why current MSL tools fall short.
The result is an MSL who spends 30 to 40 percent of their time on data aggregation, administrative tasks, and context-switching between systems. This is not a rough estimate — it is a figure that appears consistently in MSL time-use surveys and has been cited in industry research for over a decade. The percentage has not improved meaningfully, despite the proliferation of tools marketed to Medical Affairs.
Beyond the time cost, fragmentation creates information loss. The insight an MSL captures in a CRM is disconnected from the KOL profile that would give it context. The territory plan does not update when a new high-priority KOL is identified. The outreach strategy is not informed by the latest publication data. Each system holds a piece of the picture, and no one — not the MSL, not their manager, not the VP of Medical Affairs — can see the whole thing.
Compliance complexity compounds the problem. Every interaction must be documented in a manner that satisfies regulatory requirements. Materials must be tracked for approval status. Fair market value considerations govern advisory board invitations. Sample and spending limits must be monitored. These are important guardrails, but when they are managed through separate processes and separate systems, they become friction that slows down every stage of the workflow.
There is also an organizational cost. When Medical Affairs leadership cannot see a unified view of KOL engagement across the team — who is being engaged, how often, on what topics, with what outcomes — strategic planning becomes reactive rather than proactive. Resource allocation decisions are made based on incomplete data. Patterns that should be visible (a competitor gaining ground in a specific geography, an emerging KOL publishing prolifically in a new indication) go undetected until it is too late to respond.
The Shift Toward Integrated Workflows
The MSL workflow does not need more tools. It needs fewer tools that do more. The industry is beginning to recognize this, and the direction of travel is clear: the future of MSL operations is an integrated platform where identification, profiling, planning, engagement, insights, and reporting exist in a single connected system.
The first and most obvious opportunity is in the research and data aggregation layers. The work of pulling publication data, trial involvement, grant history, and payment records into a KOL profile is entirely automatable. These are public data sources with structured APIs. There is no reason for a PhD-trained scientist to spend an hour manually assembling information that a well-designed system could compile in seconds. AI is particularly well-suited to this task — not just for aggregation, but for synthesis. Summarizing a physician's research trajectory, flagging recent publications that are relevant to the company's therapeutic focus, and identifying shifts in a KOL's areas of interest are all tasks where machine learning and large language models can meaningfully augment human judgment.
The second opportunity is in workflow continuity. When KOL identification feeds directly into profiling, and profiling feeds into outreach planning, and outreach planning is informed by the latest data, each stage of the workflow becomes more effective because it builds on the work of the previous stage rather than starting from scratch. An MSL preparing for a meeting should not need to re-research a KOL they have already profiled — the system should surface what has changed since their last interaction, what the KOL has published recently, and what topics are most likely to generate a productive discussion.
The third opportunity is in insights utilization. When insights are captured in the same system that holds KOL profiles, territory data, and engagement history, they can be automatically contextualized, categorized, and routed. A pattern that would be invisible in a CRM text field — for example, that three MSLs in different territories have independently heard the same concern about a dosing regimen — becomes detectable when insights are structured and connected.
Platforms like Bionara are building this integrated layer — connecting public data sources, automating the research-intensive stages of the workflow, and giving MSL teams a unified view of their KOL landscape. But the broader point is not about any single vendor. It is that the fragmented status quo is no longer defensible. The data exists. The technology exists. The only question is how quickly Medical Affairs organizations will demand the same operational infrastructure that commercial teams have had for years.
For MSLs, the shift means more time doing what they were trained for — scientific exchange, relationship building, strategic insight generation — and less time on the administrative work that currently consumes their days. For Medical Affairs leaders, it means visibility into engagement patterns, insight trends, and team performance that is currently impossible to achieve. And for the physicians MSLs serve, it means interactions that are more relevant, more prepared, and more valuable.
Organizations that have already made this shift are beginning to report the results: faster KOL identification, higher engagement rates, richer insights, and MSL teams that are measurably more productive. For examples of what this looks like in practice, see our case studies.
The MSL profession has spent two decades proving its value to the pharmaceutical industry. The next decade will be about giving MSLs the infrastructure to deliver that value at scale. The workflow does not need to be reinvented. It needs to be connected.
Key Takeaways
- The MSL workflow spans seven distinct stages — from KOL identification through impact measurement — each with its own data requirements, tools, and stakeholders. Understanding the full workflow is a prerequisite for improving any part of it.
- KOL profiling is the foundation of MSL credibility. The quality of every downstream interaction depends on the depth and currency of the research that precedes it. Manual profiling is thorough but unsustainable at scale.
- Insights capture is the most under-leveraged stage of the workflow. MSLs generate strategic intelligence with every interaction, but current systems are not designed to surface, synthesize, or route that intelligence to decision-makers.
- Fragmentation is the core problem. MSLs do not lack tools — they lack connected tools. The typical MSL workflow touches five or more disconnected systems, and the resulting data loss and time cost are substantial.
- Traditional MSL metrics measure activity, not impact. The industry needs better frameworks for evaluating MSL effectiveness — ones that account for insight quality, relationship depth, and strategic contribution, not just interaction volume.
- Integrated platforms are the future. When identification, profiling, planning, engagement, and insights live in a single system, MSLs reclaim the time currently lost to administrative work — and Medical Affairs gains the visibility it needs to operate strategically.